CLE

DEVICE2 trials

Sponsors

Impax Laboratories, LLC, Shandong University

Conditions

Flow DeterminationParkinson's Disease

Phase 3

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

CompletedNCT01130493

Impax Laboratories, LLCParkinson's Disease

Start: 2010-05-31End: 2012-01-31Updated: 2019-10-29

Unknown Phase

Real-time Observation of Microcirculatory Hemodynamics in Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy

Shandong UniversityFlow Determination

Start: 2015-03-31End: 2015-11-30Target: 94Updated: 2015-11-03

Related Papers

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations

Parkinson s Disease2018-10-224 citations